Omalizumab |
Catalog No.GC18662
One-Click Copy Product Info
|
Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E (IgE) with a KD value of 0.393nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 242138-07-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E (IgE) with a KD value of 0.393nM[1]. Omalizumab is a human IgG1 kappa antibody that binds with high specificity to free IgE, which is widely present in human blood and tissue fluid[2]. Omalizumab inhibits the binding of IgE to FcεRI on mast cells and basophils by binding to an antigenic epitope on IgE that overlaps with the binding site of FcεRI[3]. Omalizumab can be used to treat severe persistent allergic asthma, nasal polyps, urticaria, and IgE-mediated food allergies[4, 5].
In vitro, treatment of human mast cell line (LAD2 cells) and basophils with Omalizumab (30, 100, 300µg/mL) for 24h promoted the dissociation of IgE bound to the surface of mast cells and basophils, inhibited key signaling events mediated by proximal phosphorylation (such as activation of Syk, PLCγ, and LAT), and reduced cell degranulation and leukotriene synthesis[6].
In vivo, subcutaneous treatment of an asthmatic model of cynomolgus monkeys with Omalizumab (10mg/kg) for 3 weeks significantly reduced airway resistance (RL) and lung dynamic compliance (Cdyn)[7].
References:
[1] Chu S Y, Horton H M, Pong E, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody[J]. Journal of allergy and clinical immunology, 2012, 129(4): 1102-1115.
[2] Lyly A, Laulajainen-Hongisto A, Gevaert P, et al. Monoclonal antibodies and airway diseases[J]. International Journal of Molecular Sciences, 2020, 21(24): 9477.
[3] Gomez G. Current strategies to inhibit high affinity FcεRI-mediated signaling for the treatment of allergic disease[J]. Frontiers in immunology, 2019, 10: 175.
[4] McCormack P L. Omalizumab: a review of its use in patients with chronic spontaneous urticaria[J]. Drugs, 2014, 74(14): 1693-1699.
[5] Wood R A, Togias A, Sicherer S H, et al. Omalizumab for the treatment of multiple food allergies[J]. New England Journal of Medicine, 2024, 390(10): 889-899.
[6] Serrano‐Candelas E, Martinez‐Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils[J]. Clinical & Experimental Allergy, 2016, 46(1): 92-102.
[7] Liu P, Pan Z, Gu C, et al. An omalizumab biobetter antibody with improved stability and efficacy for the treatment of allergic diseases[J]. Frontiers in immunology, 2020, 11: 596908.
| Cell experiment [1]: | |
|
Cell lines |
LAD2 cells |
|
Preparation Method |
LAD2 cells were sensitized overnight with IgEB (100 ng/mL) in culture media. The following day, the cells were washed three times in Tyrode’s buffer to eliminate unbound IgE, were subsequently incubated with Omalizumab or hIgG at different concentrations (high-dose experiments: 2, 1, 0.5, and 0.25mg/mL; or low-dose experiments: 300, 100 and 30µg/mL) in culture media and for different periods of time (30min, 3h, 24h), and were then stimulated with streptavidin for varying periods of time. Supernatants were collected for CysLT measurement, and the cells were used for WB analysis or FACS staining. |
|
Reaction Conditions |
0.25, 0.5, 1, 2mg/mL or 30, 100, 300µg/mL; 30min, 3h, 24h |
|
Applications |
Omalizumab dissociates pre-bound IgE from mast cells, resulting in a reduction of proximal phosphorylation-mediated signalling events (Syk, PLCγ, and LAT) and in a decrease in degranulation and leukotriene synthesis. |
| Animal experiment [2]: | |
|
Animal models |
Cynomolgus monkeys |
|
Preparation Method |
3-7 years old male cynomolgus monkeys weighing between 3 and 7 kg were used. To develop the allergic asthma models, monkeys were sensitized with dinitrophenyl-Ascaris suum (DNP-As) allergen. After modeling, monkeys received a dose of 10mg/kg test antibody (AB1904Am15) once a week via subcutaneous administration for 3 weeks. Humanized IgG1 antibody was used as isotype control. Omalizumab was used as a positive control. Airway resistance (RL) and lung dynamic compliance (Cdyn) were measured at 24h post 1st and 3rd dosing. |
|
Dosage form |
10mg/kg; 3 weeks; s.c. |
|
Applications |
Monkeys treated with AB1904Am15 or Omalizumab showed significant decreases in RL and Cdyn at 24 hours after the first and third doses, compared to the isotype control group. |
|
References: |
|
| Cas No. | 242138-07-4 | SDF | |
| Formula | C6450H9916N1714O2023S38 | M.Wt | 145056.09 |
| Solubility | Storage | Store at -80°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.9 μL | 34.5 μL | 68.9 μL |
| 5 mM | 1.4 μL | 6.9 μL | 13.8 μL |
| 10 mM | 0.7 μL | 3.4 μL | 6.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)